These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 15112179

  • 1. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.
    Am J Kidney Dis; 2004 May; 43(5):877-90. PubMed ID: 15112179
    [Abstract] [Full Text] [Related]

  • 2. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
    Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.
    Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
    [Abstract] [Full Text] [Related]

  • 3. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.
    Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.
    J Am Soc Nephrol; 1998 Aug; 9(8):1427-32. PubMed ID: 9697664
    [Abstract] [Full Text] [Related]

  • 4. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
    Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
    [Abstract] [Full Text] [Related]

  • 5. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
    Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V.
    Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.
    Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z.
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):299-306. PubMed ID: 20056760
    [Abstract] [Full Text] [Related]

  • 7. Interventions for metabolic bone disease in children with chronic kidney disease.
    Hahn D, Hodson EM, Craig JC.
    Cochrane Database Syst Rev; 2015 Nov 12; 2015(11):CD008327. PubMed ID: 26561037
    [Abstract] [Full Text] [Related]

  • 8. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb 12; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
    Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.
    Am J Kidney Dis; 2001 Mar 12; 37(3):532-43. PubMed ID: 11228177
    [Abstract] [Full Text] [Related]

  • 12. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Mar 12; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA, Lerner G, Warady BA, Dell KM, Greenbaum LA, Ariceta G, Hoppe B, Linde P, Lee HJ, Eldred A, Dufek MB.
    Pediatr Nephrol; 2017 Jul 12; 32(7):1221-1232. PubMed ID: 28332096
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.
    Am J Kidney Dis; 2009 Feb 12; 53(2):197-207. PubMed ID: 19110359
    [Abstract] [Full Text] [Related]

  • 15. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
    Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB.
    Kidney Int; 2011 Jan 12; 79(1):112-9. PubMed ID: 20861820
    [Abstract] [Full Text] [Related]

  • 16. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.
    Nefrologia; 2015 Jan 12; 35(4):363-73. PubMed ID: 26306956
    [Abstract] [Full Text] [Related]

  • 17. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW.
    Am J Nephrol; 2019 Jan 12; 49(4):284-293. PubMed ID: 30878999
    [Abstract] [Full Text] [Related]

  • 18. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun 12; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 19. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct 12; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 20. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
    Martin KJ, González EA, Gellens ME, Hamm LL, Abboud H, Lindberg J.
    Am J Kidney Dis; 1998 Oct 12; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.